On track to exceed $100 billion revenue first time
JNJ reported solid Q2 2026 with 5.6% operational sales growth and raised full-year guidance. New product launches (Icotide, Tremfya, Tecvaili) drove strong pharma performance, while MedTech was impacted by a China inventory drag and a soft quarter in heart recovery (Abiomed). Management expressed confidence in accelerating growth into 2027. Operational sales growth of 5.6% (ex-Stelara, double-digit); raised full-year operational sales midpoint to $100.6B and adjusted EPS to $11.50-11.65.
Buzzberg readOn track to exceed $100 billion revenue first timeJNJ reported solid Q2 2026 with 5.6% operational sales growth and raised full-year guidance. New product launches (Icotide, Tremfya, Tecvaili) drove strong pharma performance, while MedTech was impacted by a China inventory drag and a soft quarter in heart recovery (Abiomed). Management expressed confidence in accelerating growth into 2027. Operational sales growth of 5.6% (ex-Stelara, double-digit); raised full-year operational sales midpoint to $100.6B and adjusted EPS to $11.50-11.65.Read full analysisCollapse analysis
JNJ reported solid Q2 2026 with 5.6% operational sales growth and raised full-year guidance. New product launches (Icotide, Tremfya, Tecvaili) drove strong pharma performance, while MedTech was impacted by a China inventory drag and a soft quarter in heart recovery (Abiomed). Management expressed confidence in accelerating growth into 2027. Operational sales growth of 5.6% (ex-Stelara, double-digit); raised full-year operational sales midpoint to $100.6B and adjusted EPS to $11.50-11.65.
Icotide launch off to a strong start: >11,000 patients, 6,000 unique prescribers, >50% commercial coverage within 90 days.
Tremfya reached $2B quarterly sales (first $2B quarter), led by #1 share in IBD new patient starts (58% in UC, >50% in Crohn's).
MedTech grew 3.6%; electrophysiology growth was ~3% but would have been ~7% ex-400bps China inventory destock; Abiomed declined 2% due to physician selectivity after a neutral UK trial.
Revenue$25.31B
+5% QoQ
EPS$2.90
+7% QoQ
Gross margin73.11%
reported
Op margin28.34%
reported
What changed this quarter
01
Guidance
On track to exceed $100 billion revenue first time
Guidance · revenue to $100.6B
02
Demand
Icatide launch: over 10,000 patients initiated
Management struck a confident tone driven by strong Q2 results (5.6% operational sales growth), raised guidance, and momentum from new product launches, with no notable shift in confidence from prior calls.
03
Guidance
Raised operational sales growth guidance by $400M
Guidance · revenue to $100.6B
04
Margins
Adjusted pre-tax operating margin expected up ~75bps
Reported gross margin was 73.11%, reinforcing the quarter's better-than-guided profitability.
AI, capex & demand read
AI
Platform & monetization
Joaquin Duato noted the debut of Carto Sound Sonata in electrophysiology as 'bringing new AI-powered imaging and mapping capabilities,' but AI was not a central topic of the call.
Demand
Bookings & conversion
Icatide launch: over 10,000 patients initiated. Management struck a confident tone driven by strong Q2 results (5.6% operational sales growth), raised guidance, and momentum from new product launches, with no notable shift in confidence from prior calls.
Capex
Investment and capacity
Joaquin Duato highlighted an investment of 'more than $1 billion to scale our U.S. fission manufacturing, packaging, and distribution capabilities' to meet growing demand, while Joe Wolk noted an expected 'approximately 75 basis point improvement' in adjusted pre-tax operating margin despite tariff headwinds.
Tone · confident
Management struck a confident tone driven by strong Q2 results (5.6% operational sales growth), raised guidance, and momentum from new product launches, with no notable shift in confidence from prior calls.
Supply-chain alpha
A1
JNJ's electrophysiology growth was depressed ~400bps due to inventory destocking in China, suggesting a broader channel correction that may affect peers with China exposure.
JNJ called out a modest cost-of-goods-sold tailwind from tariffs in medtech (offset other headwinds), implying some near-term tariff recoupment that may be incremental for the sector.
“Cost of goods sold leveraged by 30 basis points driven by favorable operational drivers and currency, partially offset by unfavorable product mix in the innovative medicine business as well as the impact of tariffs in the med tech business.”
JNJ management acknowledges that AbbVie's Skyrizi is maintaining share in IBD/psoriasis despite Tremfya's strong growth, indicating ongoing competitive pressure in the IL-23 market.
Hi, thank you so much for the question. My question is on Trimfiya. In GI, Trimfiya seems to have an edge over SkyRizzy, yet SkyRizzy is holding its own. So my question is, to what do you attribute SkyRizzy's ability to hold share? Thank you.
JNJ's electrophysiology growth was depressed ~400bps due to inventory destocking in China, suggesting a broader channel correction that may affect peers with China exposure. — If this is an industry-wide destocking, other medtech companies (Boston Scientific, Medtronic) may similarly see an EP growth headwind in coming quarters, beyond just JNJ.
… 3.6%, with growth of 3.9% in the U.S. and 3.2% outside the U.S. Acquisitions and divestitures had a net negative impact of 10 basis points on worldwide growth. Overall cardiovascular grew 3.1%, which is lower than our recent trend primarily due to headwinds in electrophysiology and abiomed. In electrophysiology, growth of 3.1% was driven by procedure growth, commercial execution, and new product performance partially offset by competitive PFA pressures. There was also a negative impact from China inventory, which we estimate to be 400 basis points. Abiy Ahmed saw a decline of 2% due to pressures on US procedures driven by usage patterns. The downturn came as physicians evaluated the results of a recent external clinical trial, which increased selectivity within the quarter, particularly in the US. The decline was partially offset by continued OUS growth, including sustained adoption of Impella 5.5. Shockwave grew double digits at 14.7%, driven by continued adoption of coronary and peripheral products, as well as new product launches. Surgery grew 2.3%, including a negative impact of approximately 40 basis points from divestitures. Growth was driven by strength of the …
JNJ called out a modest cost-of-goods-sold tailwind from tariffs in medtech (offset other headwinds), implying some near-term tariff recoupment that may be incremental for the sector. — JNJ's ability to partially offset tariff costs through price or mix suggests a more resilient margin structure, contrasting with competitors who may not have similar leverage.
… offset by competitive pressures in the U.S. Orthopedics growth for the quarter was 4.2%, primarily driven by new product launches such as Volt and Trauma, and strong commercial execution across the portfolio. Now, turning to our Consolidated Statement of Earnings for the second quarter of 2026. I'd like to highlight a few noteworthy items that have changed compared to the same quarter of last year. Cost of goods sold leveraged by 30 basis points driven by favorable operational drivers and currency, partially offset by unfavorable product mix in the innovative medicine business as well as the impact of tariffs in the med tech business. Selling, marketing, and administrative expenses deleveraged by 60 basis points driven by increased investments in our new product launches. Research and development leveraged by 40 basis points primarily driven by expense phasing in the innovative medicine business partially offset by increased investment in med tech. Interest income and expense was a net expense of $62 million as compared to $48 million of expense in the second quarter of 2025. Other income and expense was a net expense of $331 million as compared to $107 million of expense in the …
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.